Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.

ABSTRACT:

Aims

We investigated the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval at clinical and supraclinical dose, considering the relative hyperosmolarity of this product.

Methods

This was a single centre, randomized, double-blind, placebo- and positive-controlled, 4-way crossover study. Forty-eight healthy male and female subjects were included to receive single intravenous (i.v.) administrations of gadopiclenol at the clinical dose of 0.1 mmol kg^-1 , standard for current gadolinium-based contrast agents, the supraclinical dose of 0.3 mmol kg^-1 , placebo and a single oral dose of 400 mg moxifloxacin.

Results

The largest time-matched placebo-corrected, mean change from-baseline in QTcF (ΔΔQTcF) was observed 3 hours a

SUBMITTER: Funck-Brentano C 

PROVIDER: S-EPMC7576613 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature